Shares of ResMed Inc. RMD slipped 3.97% to $204.54 Tuesday, on what proved to be an all-around poor trading session for the ...

In a welcome move, ResMed saw its Relative Strength Rating rise from 65 to 78 on Tuesday. Please watch the video at Investors ...

ResMed RMD shares rallied 3.8% in the last trading session to close at $213. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This ...

F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific, Siemens Healthineers AG, and QIAGEN Group LeadDublin, April 08, 2025 (GLOBE NEWSWIRE) -- The "Respiratory Disease Testing ...

Shares of ResMed Inc. RMD rallied 3.82% to $213.00 Monday, on what proved to be an all-around rough trading session for the ...

SAN DIEGO – Resmed has announced that its home sleep apnea test, NightOwl, is now available across the U.S.

Home CPAP device maker Resmed is launching a small, disposable wearable to help diagnose cases of obstructive sleep apnea.  | ...

NightOwl, an FDA-cleared home sleep apnea test (HSAT) offers a simplified, accurate, efficient way to diagnose obstructive sleep apnea (OSA). It adds another offering to Resmed’s portfolio, which is ...

NightOwl is now widely available across the United States. Individuals interested in NightOwl should speak with their healthcare provider for more information. To learn more, visit: https://www.resmed ...

ResMed Inc. (NYSE:RMD – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the sixteen ratings firms that are covering the company, Marketbeat.com reports.

Companies valued at $10 billion or more are generally classified as “large-cap” stocks, and ResMed fits this criterion perfectly. The company operates through two segments - Sleep and ...